Januvia licenced for triple therapy

Januvia (sitagliptin) has had its licence extended to include use in triple therapy alongside metformin and a sulfonylurea or a glitazone in type II diabetes inadequately controlled by dual therapy.

The dosage of metformin and glitazone should be maintained and the Januvia dose administered concomitantly.

If it is used in combination with a sulfonylurea, the dose of sulfonylurea may need to be lowered to reduce the risk of hypoglycaemia. The recommended dose of Januvia is 100mg once daily.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...